Systemic manifestation and co-morbidity in COPD are associated with circulating markers of aging
- Conditions
- 10024967COPD
- Registration Number
- NL-OMON39160
- Lead Sponsor
- niversiteit Maastricht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 800
For the COPD patients: diagnosis of COPD according to the American Thoracic Society (ATS) GOLD guidelines (FEV1 < 80% predicted and FEV1/FVC < 70% [18]; both male and female, age-range from 45 to 75 y; no respiratory tract infection or exacerbation of the disease for < 4 weeks before the study; capable of providing informed consent.
For the healthy subjects: subjects without the objectively diagnosed diseases assessed in the present study: COPD, untreated diabetes mellitus type II, severe and untreated osteoporosis, severe renal failure or heart failure. Both male and female, age-range from 45 to 75 y will be included in the study.
For the COPD patients and controls: any kind of carcinogenic pathology <5 y before study participation; chronic use of oral corticosteroids > 10mg/day; participation in any other studies involving investigational or marketed products concomitantly or < 4 weeks prior to entry into the study, investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Part I of the study: Markers of accelerated aging in blood, and objective<br /><br>outcomes of co-morbidity; Part II of the study: circulating hepatokines; Part<br /><br>III of the study: respiratory microbiome analysis.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Markers of systemic COPD phenotypes (markers of systemic inflammation and<br /><br>oxidative stress). The respiratory microbiome related to clinical<br /><br>characteristics.</p><br>